<DOC>
	<DOCNO>NCT01210352</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness , tolerability , safety oxymorphone immediate release ( IR ) oral liquid analgesic acute postoperative pain pediatric subject .</brief_summary>
	<brief_title>Effectiveness , Safety , Tolerability Study Oxymorphone Immediate Release ( IR ) Oral Liquid Post Surgical Pediatric Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Oxymorphone</mesh_term>
	<criteria>1 . Males females 2 ≤12 year age . Females childbearing potential must practice abstinence use medically acceptable form contraception ( eg , intrauterine device , hormonal birth control , double barrier method ) . For purpose study , peri postpubertal female consider childbearing potential unless biologically sterile surgically sterile 1 year 2 . Subjects must least 10 kg BMI ≤30 3 . Scheduled surgery oral opioid analgesia need manage postoperative pain least 24 hour ( SingleDose Phase ) 48 hour ( MultipleDose Phase ) follow intraoperative and/or postoperative parenteral analgesia 4 . Be hospital inpatient , expect hospitalize least 24 hour ( SingleDose Phase ) 48 hour ( MultipleDose Phase ) follow initial administration oxymorphone immediate release 5 . Available lab result , either intraoperatively ( prior surgical incision ) within 21 day preoperatively , clinical chemistry hematology laboratory analytes ( result must review Investigator study eligibility ) 6 . Able provide pain assessment evaluation use ageappropriate instrument provide protocol 7 . On intravenous analgesic regimen utilize shortacting opioid analgesic follow surgery AND anticipate switched oral opioid part analgesic regimen ( accord institution SOC ) 8 . Demonstrated ability tolerate clear fluid follow surgery accord SOC institution 9 . Informed nature study write informed consent obtain legally responsible parent ( ) /legal guardian ( ) 10 . Provided assent accordance IRB requirement 11 . Line place blood sample 1 . Known allergy sensitivities oxymorphone opioid analgesic 2 . Known sensitivity component study drug 3 . Life expectancy &lt; 4 week 4 . Positive pregnancy test screening ( female reproductive age ) 5 . Pregnant and/or lactate 6 . Cyanotic heart disease 7 . Respiratory , hepatic , renal , neurological , psychological disease , clinically significant condition would , Investigator 's opinion , preclude participation study 8 . Preoperative opioids administer period 72 hour duration 9 . Abdominal trauma would interfere absorption study drug 10 . Increased intracranial pressure 11 . Respiratory condition require intubation 12 . History uncontrolled seizure manage anticonvulsant 13 . Significant prior history substance abuse alcohol abuse 14 . Received investigational drug within 30 day prior first dose study drug , schedule receive investigational drug oxymorphone HCl immediaterelease oral liquid course study 15 . Received monoamine oxidase inhibitor ( MAOI ) within 14 day prior start study drug 16 . Received oxycodone oxymorphone within 48 hour prior study start 17 . Investigator anticipate subject and/or parent ( ) /legal guardian ( ) would unable comply protocol 18 . Subject ( and/or parent [ ] /legal guardian [ ] ) ( ) unable communicate effectively study personnel ageappropriate level</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>surgical pain</keyword>
	<keyword>acute pain</keyword>
	<keyword>Acute Post Surgical Pain</keyword>
</DOC>